IL108501A - Antibodies and pharmaceutical compositions containing them - Google Patents

Antibodies and pharmaceutical compositions containing them

Info

Publication number
IL108501A
IL108501A IL10850194A IL10850194A IL108501A IL 108501 A IL108501 A IL 108501A IL 10850194 A IL10850194 A IL 10850194A IL 10850194 A IL10850194 A IL 10850194A IL 108501 A IL108501 A IL 108501A
Authority
IL
Israel
Prior art keywords
antibody
bat
cell line
cells
hybridoma cell
Prior art date
Application number
IL10850194A
Other languages
English (en)
Other versions
IL108501A0 (en
Inventor
Britta Hardy
Abraham Novogrodsky
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Priority to IL10850194A priority Critical patent/IL108501A/en
Publication of IL108501A0 publication Critical patent/IL108501A0/xx
Priority to CN95192406A priority patent/CN1052733C/zh
Priority to PCT/US1995/001137 priority patent/WO1995020605A1/en
Priority to MD96-0296A priority patent/MD1374G2/ro
Priority to US08/380,857 priority patent/US5897862A/en
Priority to AU18686/95A priority patent/AU693526B2/en
Priority to JP52021095A priority patent/JP3478398B2/ja
Priority to SI9530125T priority patent/SI0742795T1/xx
Priority to EP95910891A priority patent/EP0742795B1/en
Priority to RU96116984/13A priority patent/RU2155190C2/ru
Priority to AT95910891T priority patent/ATE171461T1/de
Priority to FI963004A priority patent/FI963004L/fi
Priority to EE9600107A priority patent/EE03285B1/xx
Priority to DE69504955T priority patent/DE69504955T2/de
Priority to CA002182289A priority patent/CA2182289C/en
Priority to ES95910891T priority patent/ES2124533T3/es
Priority to DK95910891T priority patent/DK0742795T3/da
Priority to MX9603080A priority patent/MX9603080A/es
Priority to NO19963168A priority patent/NO317020B1/no
Priority to LT96-115A priority patent/LT4225B/lt
Priority to LVP-96-317A priority patent/LV11624B/en
Publication of IL108501A publication Critical patent/IL108501A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL10850194A 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them IL108501A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
DK95910891T DK0742795T3 (da) 1994-01-31 1995-01-30 Immunstimulerende monoklonale antistoffer
AT95910891T ATE171461T1 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
EE9600107A EE03285B1 (et) 1994-01-31 1995-01-30 Immuunsust stimuleerivad monoklonaalsed antikehad
MD96-0296A MD1374G2 (ro) 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
US08/380,857 US5897862A (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
AU18686/95A AU693526B2 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
JP52021095A JP3478398B2 (ja) 1994-01-31 1995-01-30 免疫刺激性モノクローナル抗体
SI9530125T SI0742795T1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
EP95910891A EP0742795B1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
RU96116984/13A RU2155190C2 (ru) 1994-01-31 1995-01-30 Иммуностимуляторные моноклональные антитела
CN95192406A CN1052733C (zh) 1994-01-31 1995-01-30 免疫刺激单克隆抗体
FI963004A FI963004L (fi) 1994-01-31 1995-01-30 Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
DE69504955T DE69504955T2 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
CA002182289A CA2182289C (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
ES95910891T ES2124533T3 (es) 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes.
NO19963168A NO317020B1 (no) 1994-01-31 1996-07-29 Immunstimulatoriske monoklonale antistoffer
MX9603080A MX9603080A (es) 1994-01-31 1996-07-29 Anticuerpos monoclonales inmuno-estimulantes.
LT96-115A LT4225B (en) 1994-01-31 1996-07-30 Immuno-stimulatory monoclonal antibodies
LVP-96-317A LV11624B (en) 1994-01-31 1996-09-06 Immuno-stimulatory monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL108501A0 IL108501A0 (en) 1994-05-30
IL108501A true IL108501A (en) 1998-10-30

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (1) US5897862A (lt)
EP (1) EP0742795B1 (lt)
JP (1) JP3478398B2 (lt)
CN (1) CN1052733C (lt)
AT (1) ATE171461T1 (lt)
AU (1) AU693526B2 (lt)
CA (1) CA2182289C (lt)
DE (1) DE69504955T2 (lt)
DK (1) DK0742795T3 (lt)
EE (1) EE03285B1 (lt)
ES (1) ES2124533T3 (lt)
FI (1) FI963004L (lt)
IL (1) IL108501A (lt)
LT (1) LT4225B (lt)
LV (1) LV11624B (lt)
MD (1) MD1374G2 (lt)
MX (1) MX9603080A (lt)
NO (1) NO317020B1 (lt)
RU (1) RU2155190C2 (lt)
WO (1) WO1995020605A1 (lt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP2243493A1 (en) 2002-07-03 2010-10-27 Ono Pharmaceutical Co., Ltd. Immunopotentiative composition
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
DK1673397T3 (da) * 2003-07-02 2011-03-07 Univ Genova Fremgangsmåde til fremstilling og evaluering af cytotoksicitet af KIR2DL NK-receptorer antistoffer
US20090123413A1 (en) * 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
MX2007013978A (es) 2005-05-09 2008-02-22 Ono Pharmaceutical Co Anticuerpos monoclonales humanos a muerte programada 1 (pd-1) y metodos para tratamiento de cancer utilizando anticuerpos anti-pd-1 solos o en combinacion con otros inmunoterapeuticos.
CN105330741B (zh) 2005-07-01 2023-01-31 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
KR101562580B1 (ko) * 2007-06-18 2015-10-22 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
ES2639857T3 (es) * 2008-02-11 2017-10-30 Cure Tech Ltd. Anticuerpos monoclonales para el tratamiento del tumor
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
BR112013032552A2 (pt) 2011-07-24 2017-12-12 Curetech Ltd variantes de anticorpos monoclonais humanizados imunomoduladores
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
PH12016501545B1 (en) 2014-03-14 2023-12-06 Immutep Sas Antibody molecules to lag-3 and uses thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
GEAP202215554A (en) 2015-07-30 2022-06-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
AU2016332725A1 (en) 2015-09-29 2018-03-22 Celgene Corporation PD-1 binding proteins and methods of use thereof
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
MX2018007089A (es) 2015-12-14 2019-01-30 Macrogenics Inc Moleculas biespecificas que tienen inmunorreactividad con pd-1 y ctla-4, y metodos de uso de las mismas.
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
SG11201901950TA (en) 2016-09-19 2019-04-29 Celgene Corp Methods of treating immune disorders using pd-1 binding proteins
CA3046082A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Antibodies and methods of use thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
MD1374F2 (en) 1999-12-31
NO963168D0 (no) 1996-07-29
FI963004A7 (fi) 1996-09-27
LT96115A (en) 1997-05-26
DE69504955D1 (de) 1998-10-29
NO963168L (no) 1996-09-27
RU2155190C2 (ru) 2000-08-27
NO317020B1 (no) 2004-07-26
WO1995020605A1 (en) 1995-08-03
ATE171461T1 (de) 1998-10-15
CN1145077A (zh) 1997-03-12
LV11624B (en) 1997-06-20
MX9603080A (es) 1998-01-31
LV11624A (en) 1996-12-20
MD1374G2 (ro) 2000-09-30
CA2182289C (en) 2003-10-21
JPH09508390A (ja) 1997-08-26
CA2182289A1 (en) 1995-08-03
JP3478398B2 (ja) 2003-12-15
AU693526B2 (en) 1998-07-02
EP0742795A1 (en) 1996-11-20
US5897862A (en) 1999-04-27
AU1868695A (en) 1995-08-15
FI963004L (fi) 1996-09-27
DE69504955T2 (de) 1999-05-27
EE03285B1 (et) 2000-08-15
CN1052733C (zh) 2000-05-24
FI963004A0 (fi) 1996-07-29
DK0742795T3 (da) 1999-06-14
ES2124533T3 (es) 1999-02-01
LT4225B (en) 1997-10-27
IL108501A0 (en) 1994-05-30
EP0742795B1 (en) 1998-09-23

Similar Documents

Publication Publication Date Title
US5897862A (en) Immuno-stimulatory monoclonal antibodies
WO1995020605A9 (en) Immuno-stimulatory monoclonal antibodies
MXPA96003080A (en) Monoclonal antibodies immuno-estimulan
US7794710B2 (en) Methods of enhancing T cell responsiveness
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
US20210214436A1 (en) Multi-specific binding proteins and improvements thereon
US6852320B2 (en) T cell inhibitory receptor compositions and uses thereof
US6197298B1 (en) Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
AU2002219229B2 (en) Means for the diagnosis and therapy of CTCL
KR19990022650A (ko) 사람 ｂ7.1 및/또는 ｂ7.2 영장류화된 형태에 특이적인 원숭이 단일클론성 항체 및 이의 약제학적 조성물
CA2179196A1 (en) Method of preventing or treating disease characterized by neoplastic cells expressing cd40
AU2015300006B2 (en) Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
US10344073B2 (en) Cell compositions and methods for cancer therapy
KR20110085038A (ko) 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
Hardy et al. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice
Saha et al. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection
JPH01126558A (ja) 抗体依存性細胞性細胞毒性の測定方法
Wang et al. Targeting solid tumors via T cell receptor complementarity-determining region 3δ in an engineered antibody
Kudo et al. Specific targeting immunotherapy of cancer with bispecific antibodies
US20240293546A1 (en) D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same
Hollingworth The manipulation of cellular immunity by monoclonal antibodies in cancer patients
Mukherjee et al. Therapeutic Efficacy of Muci-Specific Cytotoxic T Lymphocytes and CD137 Co-Stimulation in a Spontaneous Mammary Cancer Model
Olson et al. Enhancing Anti-Tumor Activity Against Glioblastoma and Neuroblastoma by Retargeting T Cells with OKT3 X Anti-EGFR

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired